Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05782920
Other study ID # 0201349
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 30, 2020
Est. completion date March 31, 2021

Study information

Verified date March 2023
Source Alexandria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to: 1. evaluate the efficacy of PRP injection and PRP injection mixed with non-cross-linked hyaluronic acid compared to the control group receiving standard therapy with topical non-cross-linked hyaluronic acid gel in the treatment of cancer therapy-induced or worsened vulvovaginal atrophy. 2. To evaluate the impact of vulvovaginal atrophy treatment on the sexual satisfaction of both partners. Patients will be divided randomly into 3 groups: Group 1: 15 female patients will receive vaginal PRP injections. Group 2: 15 female patients will receive vaginal PRP injections combined with non-cross-linked hyaluronic acid. Group 3: 15 female patients will receive topical non-cross-linked hyaluronic acid gel as a control group.


Description:

1. The first group will receive two treatment of sub-mucosal PRP injection at the outer 3 cm of the vagina with one month interval in between. (17) 2. The second group will receive two treatment of PRP injection mixed with non-cross linked hyaluronic acid at the outer 3 cm of the vagina with one month interval in between. 9. 3-The third group will receive one applicator (5gm) three times per week of topical hyaluronic acid gel for vaginal application which will be prepared in the faculty of pharmacy for 2 months. Clinical assessment Patients will be assessed for symptoms and signs of vulvovaginal atrophy (VVA) at baseline, one month, two months, and, three months after the end of treatment. 1. Vulvovaginal atrophy (VVA) symptoms (dryness, dyspareunia) will be assessed on a subjective 10-point scale. Also, patient satisfaction with each type of treatment will be assessed with a questionnaire at the end of treatment and they will be asked if they wish to repeat the treatment to maintain effectiveness over time (yes or No). 2. For assessment of VVA signs on physical examination, vaginal health index including assessment of pH, overall elasticity, epithelial mucosa, fluid secretion type, and consistency and moisture will be used as an objective method of evaluation of therapy. 3. Assessment of sexual satisfaction of both male and female partners: Sexual satisfaction was measured using the Arabic version of the Index of Sexual Satisfaction (ISS) and female sexual function index (FSFI) questionnaire.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date March 31, 2021
Est. primary completion date March 31, 2021
Accepts healthy volunteers No
Gender Female
Age group N/A to 70 Years
Eligibility Inclusion Criteria: - Patients have symptoms of VVA (vaginal dryness, burning, itching or dyspareunia) - Patients with vaginal health index < 15. - All patients have already finished cancer therapy or are on anti-estrogen treatment. - Married sexually active - Patients who are not receiving any VVA treatment for at least 30 days before starting therapy. Exclusion Criteria: - Active or recent history of vulvovaginal inflammation or infection - History of vulvar or vaginal cancer. - Suspicious lesion in the vulvovaginal area on the gynecological examination

Study Design


Related Conditions & MeSH terms

  • Atrophy
  • Genitourinary Syndrome of Menopause

Intervention

Device:
Platelet rich plasma
PRP can be considered a concentrate of autologous platelet-derived growth factors with known efficacy in tissue regeneration and wound healing.
non cross-linked hyaluronic acid
HA filling is a known modality for rejuvenation
topical HA gel
the standard treatment of vaginal atrophy and dryness

Locations

Country Name City State
Egypt Alexandria University Alexandria

Sponsors (1)

Lead Sponsor Collaborator
Alexandria University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Hersant B, SidAhmed-Mezi M, Belkacemi Y, Darmon F, Bastuji-Garin S, Werkoff G, Bosc R, Niddam J, Hermeziu O, La Padula S, Meningaud JP. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause. 2018 Oct;25(10):1124-1130. doi: 10.1097/GME.0000000000001122. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Vulvovaginal atrophy vaginal dryness severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms before treatment
Primary Vulvovaginal atrophy vaginal dryness severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms after 1 month
Primary Vulvovaginal atrophy vaginal dryness severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms after 2 months
Primary Vulvovaginal atrophy vaginal dryness severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms 3 months follow up
Primary Vulvovaginal atrophy dyspareunia severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms before treatment
Primary Vulvovaginal atrophy dyspareunia severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms after 1 month
Primary Vulvovaginal atrophy dyspareunia severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms after 2 months
Primary Vulvovaginal atrophy dyspareunia severity scores scores from 0-10 where 0: no symptoms, 1-3: mild symptoms, 4-6: moderate symptoms, 7-10: severe symptoms 3 months follow up
Primary Vaginal health index total score scores range from 5-25 with lower scores signifying greater atrophy before treatment
Primary Vaginal health index total score scores range from 5-25 with lower scores signifying greater atrophy after 1 month
Primary Vaginal health index total score scores range from 5-25 with lower scores signifying greater atrophy after 2 months
Primary Vaginal health index total score scores range from 5-25 with lower scores signifying greater atrophy 3 months follow up
See also
  Status Clinical Trial Phase
Recruiting NCT05812924 - A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause Phase 2
Completed NCT04535323 - Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients With Stage 0-III Breast Cancer Phase 1
Completed NCT03331328 - MonaLisa Touch Randomized Double-Blind Placebo Controlled Study N/A
Recruiting NCT04746456 - Vulvovaginal Atrophy Questionnaire (VVAQ): Psychometric Validation of a Novel PROM
Withdrawn NCT04606550 - MonaLisa Laser Intervention for Post-Menopausal Breast Cancer Patients: A SHE CAN Study N/A
Completed NCT04705883 - Vaginal Prasterone In Vaginal Atrophy In Breast Cancer Survivors Phase 4
Recruiting NCT05953090 - VALOR: Vaginal Atrophy & Long-term Observation of Recovery N/A
Active, not recruiting NCT04619485 - Sexual and Vaginal Health in Breast Cancer Women Receiving Aromatase Inhibitors Before and After CO2 Laser Therapy N/A
Completed NCT04607798 - Multi-polar RF and PEMF for Treatment of Vulvovaginal Atrophy N/A
Recruiting NCT06124820 - RCT Comparing Intravaginal Laser Therapy to Sham in Post-menopausal Women With Recurrent Urinary Tract Infections N/A
Completed NCT05561972 - The Ultrasonographic Assessment of Efficacy of Injectable Hyaluronic Acid for Genitourinary Syndrome of Menopause N/A
Recruiting NCT05571527 - Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause N/A
Recruiting NCT04677491 - Effects of Ospemifene on Brain Activation Patterns in Women With Sexual Interest-arousal Disorders Phase 4
Not yet recruiting NCT06425978 - Efficacy of the Use of Cellular Matrix/ A-CP-HA Kit Phase 4
Recruiting NCT05672901 - Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause N/A
Recruiting NCT03782480 - Examining Effects of Intrarosa in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy Phase 3
Recruiting NCT06028009 - PRP Injections for Genitourinary Syndrome of Menopause N/A
Not yet recruiting NCT06007027 - Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors N/A
Terminated NCT03857893 - New Non-Hormonal Treatment by Radiofrequency for Vulvo-Vaginal Atrophy N/A
Completed NCT05464654 - Vaginal Biorevitalization With Polydeoxyribonucleotides for the Improvement of the Genitourinary Syndrome of Menopause N/A